BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Khaderi S, Kanwal F. Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology 2022. [PMID: 35388520 DOI: 10.1002/hep.32512] [Reference Citation Analysis]
2 Marquardt P, Liu PH, Immergluck J, Olivares J, Arroyo A, Rich NE, Parikh ND, Yopp AC, Singal AG. Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatol Commun 2021;5:1481-9. [PMID: 34510836 DOI: 10.1002/hep4.1735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gao X, Jia X, Xu M, Xiang J, Lei J, Li Y, Lu Y, Zuo S. Regulation of Gamma-Aminobutyric Acid Transaminase Expression and Its Clinical Significance in Hepatocellular Carcinoma. Front Oncol 2022;12:879810. [DOI: 10.3389/fonc.2022.879810] [Reference Citation Analysis]
4 Sun K, Wang H, Zhang D, Li Y, Ren L. Depleting circ_0088364 restrained cell growth and motility of human hepatocellular carcinoma via circ_0088364-miR-1270-COL4A1 ceRNA pathway. Cell Cycle 2021;:1-15. [PMID: 34951563 DOI: 10.1080/15384101.2021.2016196] [Reference Citation Analysis]
5 Lin N, Lin Y, Xu J, Liu D, Li D, Meng H, Gallant MA, Kubota N, Roy D, Li JS, Gorospe EC, Sherman M, Gish RG, Abou-Alfa GK, Nguyen MH, Taggart DJ, Van Etten RA, Hoshida Y, Li W. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35244350 DOI: 10.1002/hep4.1918] [Reference Citation Analysis]
6 Woolen SA, Singal AG, Davenport MS, Troost JP, Khalatbari S, Mittal S, Siddiqui S, Fobar A, Morris J, Odewole M, Tapper EB, Pillai A, Parikh ND. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00202-0. [PMID: 33618022 DOI: 10.1016/j.cgh.2021.02.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
7 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
8 Jepsen P, West J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J Hepatol 2021;74:1234-9. [PMID: 33465402 DOI: 10.1016/j.jhep.2020.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
10 Cholankeril G, Kanwal F. NAFLD and HCC: Time to Bridge the Gap. Hepatology 2021;74:2336-8. [PMID: 34164841 DOI: 10.1002/hep.32025] [Reference Citation Analysis]
11 Govalan R, Luu M, Lauzon M, Kosari K, Ahn JC, Rich NE, Nissen N, Roberts LR, Singal AG, Yang JD. Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. Hepatol Commun 2021. [PMID: 34558830 DOI: 10.1002/hep4.1795] [Reference Citation Analysis]
12 Singal AG, Reddy S, Radadiya Aka Patel H, Villarreal D, Khan A, Liu Y, Cerda V, Rich NE, Murphy CC, Tiro JA, Kramer JR, Hernaez R. Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01309-4. [PMID: 34902568 DOI: 10.1016/j.cgh.2021.12.014] [Reference Citation Analysis]
13 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
14 Chu J, Cholankeril G, Yu X, Rana A, Natarajan Y, El-Serag HB, Kramer J, Kanwal F. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci 2022. [PMID: 35759159 DOI: 10.1007/s10620-022-07565-x] [Reference Citation Analysis]
15 Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31725-0. [PMID: 33387668 DOI: 10.1016/j.cgh.2020.12.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
16 Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, de Ledinghen V, Zoulim F, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. JHEP Rep 2021;3:100298. [PMID: 34142073 DOI: 10.1016/j.jhepr.2021.100298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Fang D, Wang MR, Guan JL, Han YY, Sheng JQ, Tian DA, Li PY. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway. Exp Cell Res 2021;406:112727. [PMID: 34370992 DOI: 10.1016/j.yexcr.2021.112727] [Reference Citation Analysis]
18 Singal AG, Chen Y, Sridhar S, Mittal V, Fullington H, Shaik M, Waljee AK, Tiro J. Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00217-2. [PMID: 33662594 DOI: 10.1016/j.cgh.2021.02.038] [Reference Citation Analysis]
19 Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in F6Publishing: 2] [Reference Citation Analysis]